Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 19/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 19/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 19/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 19/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 19/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 19/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754585 | 0.92 | HDAC3 (0.86) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL756891 | 0.88 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754792 | 0.88 | HDAC6 (0.78) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL753775 | 0.87 | HDAC3 (0.76) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754645 | 0.87 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL756326 | 0.84 | HDAC3 (0.71) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754658 | 0.83 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754771 | 0.80 | HDAC6 (0.66) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL754602 | 0.79 | HDAC3 (0.85) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12295595 | 0.78 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885710-B1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-19 | — | — | EP | disclosed |
| US-8377935-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-21 | — | — | US | disclosed |
| US-8138198-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE (FR) | 2012-03-20 | — | — | US | disclosed |
| US-8138198-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE (FR) | 2012-03-20 | — | — | US | disclosed |
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE | 2009-09-03 | — | — | US | disclosed |
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | ANGIBAUD PATRICK RENE | 2009-09-03 | — | — | US | disclosed |
| WO-2006122926-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221580-A1 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC2 2/4885 |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.